Relay Therapeutics Shares Reclaim Offer Price as Traders Eye June
Relay Therapeutics traded up on Thursday, staying above last week’s public offer price. Some investors moved past dilution concerns and turned attention to two June investor events, with management expected to field questions about lead asset zovegalisib. Shares were at $14.50 as of 11:46 a.m. EDT, up roughly 0.5%. The SPDR S&P Biotech ETF was also up 0.6%, and the iShares Nasdaq Biotechnology ETF added 0.9%. Relay is moving fast. The company said Wednesday that management will appear at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs Global Healthcare Conference on June 8. Those showings come less than two weeks after Relay ran a stock sale and dropped new clinical data in its rare-disease program.